Fiche société
Odense University Hospital
Traitements, essais et publications liés.
Traitements3programmes
Essais1liés
Publications3liées
SourceDBlocale
Traitements
3| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| Turning OFF the neuromodulatorA multi-center double-blinded placebo-controlled randomized clinical trial. The patients will be randomized into two groups. To investigate the efficacy of SNM to improve the key bladder diary variables compared to placebo (i.e. sham) for patients with MS having refractory neurogenic lower urinary tract dysfunction (NLUTD). After first step SNM-procedure and a 3-4 weeks test period patients with more than 50% improvement in the key bladder diary variables will have the IPG implanted. After a month of optimization patients will into two groups: IPG ON or IPG OFF. Period of randomization: four months. Number anticipated to be included: 60 patients | SEP | Non applicable | Traitement symptomatique | Denmark | À vérifier |
| Turning ON the neuromodulatorA multi-center double-blinded placebo-controlled randomized clinical trial. The patients will be randomized into two groups. To investigate the efficacy of SNM to improve the key bladder diary variables compared to placebo (i.e. sham) for patients with MS having refractory neurogenic lower urinary tract dysfunction (NLUTD). After first step SNM-procedure and a 3-4 weeks test period patients with more than 50% improvement in the key bladder diary variables will have the IPG implanted. After a month of optimization patients will into two groups: IPG ON or IPG OFF. Period of randomization: four months. Number anticipated to be included: 60 patients | SEP | Non applicable | Traitement symptomatique | Denmark | À vérifier |
| Turning ON the neuromodulatorA multi-center double-blinded placebo-controlled randomized clinical trial. The patients will be randomized into two groups. To investigate the efficacy of SNM to improve the key bladder diary variables compared to placebo (i.e. sham) for patients with MS having refractory neurogenic lower urinary tract dysfunction (NLUTD). After first step SNM-procedure and a 3-4 weeks test period patients with more than 50% improvement in the key bladder diary variables will have the IPG implanted. After a month of optimization patients will into two groups: IPG ON or IPG OFF. Period of randomization: four months. Number anticipated to be included: 60 patients | SEP | Non applicable | Traitement symptomatique | Denmark | À vérifier |
Essais cliniques
1| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Turning ON the neuromodulator | SEP | Non applicable | NCT05380856 | Sacral Neuromodulation for Neurogenic Lower Urinary Tract, Bowel and Sexual Dysfunction | RECRUITING |
Publications
3| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| Turning OFF the neuromodulator | Management of a Hypoglossal Nerve, Upper Airway Stimulator in the Pain Patient: Safety Considerations. | Pain practice : the official journal of World Institute of Pain | ||
| Turning OFF the neuromodulator | Patients' Perspectives and Challenges with Sacral Neuromodulation Implantable Pulse Generator. | International urogynecology journal | ||
| Turning OFF the neuromodulator | A neuroprosthesis for restoring hand movement and sensation in a person with complete tetraplegia. | Nature medicine |